Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07184502
PHASE1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

View on ClinicalTrials.gov

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) parts.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT003 Injection in Healthy Volunteers and Overweight or Obese Volunteers

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2025-10-16

Completion Date

2026-10-10

Last Updated

2026-01-30

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

ZT003

ZT003 is administered as a single subcutaneous injection at different dose levels.

DRUG

ZT003

ZT003 administered as multiple subcutaneous injections at different dose levels.

DRUG

Placebo

Matching placebo administered subcutaneously.

Locations (1)

Nucleus Network Brisbane

Brisbane, Queensland, Australia